Ocular adnexal lymphoma - a retrospective study and review of the literature.
MALT lymphoma
conjunctival lymphoma
lymphoma treatment
ocular adnexal lymphoma
orbital lymphoma
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
received:
30
04
2024
accepted:
12
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
To review the characteristics of all Slovenian patients with ocular adnexal lymphoma (OAL) in the period of 24 years with the aim of evaluating demographic data, lymphoma location and type, disease stage, treatment modality, local control rate and survival rate. All patients with histologically diagnosed OAL in the main tertiary centre of Slovenia, Eye Hospital, University Medical Centre Ljubljana, who were treated at Institute of Oncology Ljubljana were included in the study. Patients' data were collected from October 1995 through April 2019. Seventy-four patients were included in the study having a median age of 68 years at diagnosis. The majority of lymphomas were of B-cell origin (98.6%). The most frequent type was the extranodal marginal zone B-cell lymphoma (MALT) (71.6%). Orbital lymphomas were diagnosed in 56 cases (75.7%) and conjunctival in 18 cases (24.3%). Ocular manifestation was the first sign of the disease in 78.4% of patients and in 67.6% of patients ocular adnexa were the only disease location. Fifty-one patients (68.9%) were treated with radiotherapy, 7 patients (9.4%) with systemic treatment, 5 patients (6.8%) with combined radiotherapy and systemic treatment and in 11 patients, biopsy and active surveillance strategy was applied (14.9%). Local control of the disease was achieved in 96.6% of treated patients. Median overall survival of the whole study group has not been reached yet. Five-year overall survival rate was 80.1% (95% CI 68.1% - 88.5%) and 5-year lymphoma specific survival rate was 87.2% (95% CI 83.2%-91.2%). OALs comprise a group of heterogeneous diseases with variable outcomes depending predominately on the patient's age and lymphoma type, with low grade lymphomas carrying good prognosis even in elderly patients.
Sections du résumé
BACKGROUND
BACKGROUND
To review the characteristics of all Slovenian patients with ocular adnexal lymphoma (OAL) in the period of 24 years with the aim of evaluating demographic data, lymphoma location and type, disease stage, treatment modality, local control rate and survival rate.
PATIENTS AND METHODS
METHODS
All patients with histologically diagnosed OAL in the main tertiary centre of Slovenia, Eye Hospital, University Medical Centre Ljubljana, who were treated at Institute of Oncology Ljubljana were included in the study. Patients' data were collected from October 1995 through April 2019.
RESULTS
RESULTS
Seventy-four patients were included in the study having a median age of 68 years at diagnosis. The majority of lymphomas were of B-cell origin (98.6%). The most frequent type was the extranodal marginal zone B-cell lymphoma (MALT) (71.6%). Orbital lymphomas were diagnosed in 56 cases (75.7%) and conjunctival in 18 cases (24.3%). Ocular manifestation was the first sign of the disease in 78.4% of patients and in 67.6% of patients ocular adnexa were the only disease location. Fifty-one patients (68.9%) were treated with radiotherapy, 7 patients (9.4%) with systemic treatment, 5 patients (6.8%) with combined radiotherapy and systemic treatment and in 11 patients, biopsy and active surveillance strategy was applied (14.9%). Local control of the disease was achieved in 96.6% of treated patients. Median overall survival of the whole study group has not been reached yet. Five-year overall survival rate was 80.1% (95% CI 68.1% - 88.5%) and 5-year lymphoma specific survival rate was 87.2% (95% CI 83.2%-91.2%).
CONCLUSIONS
CONCLUSIONS
OALs comprise a group of heterogeneous diseases with variable outcomes depending predominately on the patient's age and lymphoma type, with low grade lymphomas carrying good prognosis even in elderly patients.
Identifiants
pubmed: 39287167
pii: raon-2024-0048
doi: 10.2478/raon-2024-0048
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-424Informations de copyright
© 2024 Lucka Boltezar et al., published by Sciendo.
Références
Mugnaini EN, Ghosh N. Lymphoma. Prim Care 2016; 43: 661–75. doi: 10.1016/j.pop.2016.07.012
doi: 10.1016/j.pop.2016.07.012
Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am 2008; 46: 175–98. doi: 10.1016/j.rcl.2008.03.005
doi: 10.1016/j.rcl.2008.03.005
Bairey O, Kremer I, Rakowsky E, Hadar H, Shaklai M. Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma. Cancer 1994; 73: 2395–99. doi: 10.1002/1097-0142(19940501)73:9<2395::AIDCNCR2820730924>3.0.CO;2-V
doi: 10.1002/1097-0142(19940501)73:9<2395::AIDCNCR2820730924>3.0.CO;2-V
Ohtsuka K, Hashimoto M, Suzuki Y. A review of 244 orbital tumors in Japanese patients during a 21-year period: origins and locations. Jpn J Ophthalmol 2005; 49: 49–55. doi: 10.1007/s10384-004-0147-y
doi: 10.1007/s10384-004-0147-y
Sjö LD. Ophthalmic lymphoma: epidemiology and pathogenesis. Acta Ophthalmol 2009; 87: 1–20. doi: 10.1111/j.1755-3768.2008.01478.x
doi: 10.1111/j.1755-3768.2008.01478.x
Coupland SE, White VA, Rootman J, Damato B, Finger PT. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 2009; 133: 1262–67. doi: 10.5858/133.8.1262
doi: 10.5858/133.8.1262
Bardenstein DS. Ocular adnexal lymphoma: classification, clinical disease, and molecular biology. Ophthalmol Clin North Am 2005; 18: 187–97. doi: 10.1016/j.ohc.2004.11.001
doi: 10.1016/j.ohc.2004.11.001
Coupland SE, Krause L, Delecluse HJ, Anagnostopoulos I, Foss HD, Hummel M, et al. Lymphoproliferative lesions of the ocular adnexa: Analysis of 112 cases. Ophthalmology 1998; 105: 1430–41. doi: 10.1016/S0161-6420(98)98024-1
doi: 10.1016/S0161-6420(98)98024-1
McKelvie PA, McNab A, Francis IC, Fox R, O’Day J. Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol 2001; 29: 387–93. doi: 10.1046/j.1442-9071.2001.d01-18.x
doi: 10.1046/j.1442-9071.2001.d01-18.x
Bernardini FP, Bazzan M. Lymphoproliferative disease of the orbit. Curr Opin Ophthalmol 2007; 18: 398–401. doi: 10.1097/ICU.0b013e3282be8fbb
doi: 10.1097/ICU.0b013e3282be8fbb
Khan SN, Sepahdari AR. Orbital masses: CT and MRI of common vascular lesions, benign tumors, and malignancies. Saudi J Ophthalmol 2012; 26: 373–83. doi: 10.1016/j.sjopt.2012.08.001
doi: 10.1016/j.sjopt.2012.08.001
Sullivan TJ, Valenzuela AA. Imaging features of ocular adnexal lymphoproliferative disease. Eye 2006; 20: 1189–95. doi: 10.1038/sj.eye.6702382
doi: 10.1038/sj.eye.6702382
Hui K-H, Pfeiffer ML, Esmaeli B. Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors. Saudi J Ophthalmol 2012; 26: 365–71. doi: 10.1016/j.sjopt.2012.08.008
doi: 10.1016/j.sjopt.2012.08.008
J R, VA W, JM C, RD G. Lymphoproliferative, leukemic, and histiocytic lesions of the orbit. In: Rootman J, editor. Diseases of the orbit: a multidisciplinary approach. 2nd Edition. Philadelphia, USA: Lippincott Williams & Wilkins; 2003; p. 385–416.
Cohen V. Treatment options for ocular adnexal lymphoma (OAL). Clin Ophthalmol 2009; 3: 689–92. doi: 10.2147/OPTH.S5828
doi: 10.2147/OPTH.S5828
Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Rouic LLL. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 2006; 108: 1451–60. doi: 10.1182/blood-2006-02-005017
doi: 10.1182/blood-2006-02-005017
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 17–29. doi: 10.1016/j.annonc.2019.10.010
doi: 10.1016/j.annonc.2019.10.010
Graue GF, Finger PT, Maher E, Della Rocca D, Della Rocca R, Lelli GJ Jr, et al. Ocular Adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. Eur J Ophthalmol 2013; 23: 344–55. doi: 10.5301/ejo.5000224
doi: 10.5301/ejo.5000224
Jezeršek Novaković B. [Recommendations for the management of patients with malignant lymphomas]. [Slovenian]. 2023. Ljubljana: Institute of Oncology Ljubljana. [internet]. [cited 2024 Mar 15]. Available at: https://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_malignimi_limfomi_2023.pdf . Published 2023.
Swerdlow S, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoetic and lmyphoid tissues . 4th edition. Lyon: IARC; 2017.
Dalvin LA, Salomão DR, Patel SV. Population-based incidence of conjunctival tumours in Olmsted County, Minnesota. Br J Ophthalmol 2018; 102: 1728–34. doi: 10.1136/bjophthalmol-2017-311530
doi: 10.1136/bjophthalmol-2017-311530
Fernández C, Henry R, Shields C, Bilyk JR, Lally SE, Eagle RC, et al. Ocular adnexal lymphoma: a single-institution retrospective study. Saudi J Ophthalmol 2021; 35: 230–8. doi: 10.4103/1319-4534.343368
doi: 10.4103/1319-4534.343368
Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol 2007; 31: 170–84. doi: 10.1097/01.pas.0000213350.49767.46
doi: 10.1097/01.pas.0000213350.49767.46
Tanenbaum RE, Galor A, Dubovy SR, Karp CL. Classification, diagnosis, and management of conjunctival lymphoma. Eye Vis 2019; 6: 22. doi: 10.1186/s40662-019-0146-1
doi: 10.1186/s40662-019-0146-1
Yen MT, Bilyk JR, Wladis EJ, Bradley EA, Mawn LA. Treatments for ocular adnexal lymphoma. Ophthalmology 2018; 125: 127–36. doi: 10.1016/j.ophtha.2017.05.037
doi: 10.1016/j.ophtha.2017.05.037
Rasmussen P, Sjo LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol 2009; 93: 1047–51. doi: 10.1136/bjo.2008.146910
doi: 10.1136/bjo.2008.146910
Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol 2019; 64: 45–66. doi: 10.1016/j.survophthal.2018.08.002
doi: 10.1016/j.survophthal.2018.08.002
Meunier J, Rouïc LL-L, Dendale R, Vincent-Salomon A, Asselain B, Arnaud P, et al. Conjunctival low-grade non-Hodgkin’s lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. Leuk Lymphoma 2006; 47: 1295–305. doi: 10.1080/10428190500518966
doi: 10.1080/10428190500518966
White WL, Ferry JA, Harris NL, Grove AS. Ocular adnexal lymphoma. Ophthalmology 1995; 102: 1994–2006. doi: 10.1016/S0161-6420(95)30764-6
doi: 10.1016/S0161-6420(95)30764-6
Knowles DM, Jakobiec FA, Mcnally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 1990; 21: 959–73. doi: 10.1016/0046-8177(90)90181-4
doi: 10.1016/0046-8177(90)90181-4
Andrew NH, Coupland SE, Pirbhai A, Selva D. Lymphoid hyperplasia of the orbit and ocular adnexa: a clinical pathologic review. Surv Ophthalmol 2016; 61: 778–90. doi: 10.1016/j.survophthal.2016.04.004
doi: 10.1016/j.survophthal.2016.04.004
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86–92. doi: 10.1016/j.radonc.2011.05.013
doi: 10.1016/j.radonc.2011.05.013
De Castro B, Peixeiro RP, Mariz JM, Oliveira Â. Ultra-low dose radiotherapy in the management of low-grade orbital lymphomas. Reports Pract Oncol Radiother 2022; 27: 467–73. doi: 10.5603/RPOR.a2022.0044
doi: 10.5603/RPOR.a2022.0044
Park J, Yea JW, Oh SA, Kim MK, Son JH, Park JW. Prospective study of 4 Gy radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma (FORMAL). Cancers 2022; 14: 4274. doi: 10.3390/cancers14174274
doi: 10.3390/cancers14174274
Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006; 17: 135–40. doi: 10.1093/annonc/mdj025
doi: 10.1093/annonc/mdj025
Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: 116–25. doi: 10.1093/annonc/mdv304
doi: 10.1093/annonc/mdv304
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(Suppl 4): iv62–71. doi: 10.1093/annonc/mdx223
doi: 10.1093/annonc/mdx223
Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone sub-type. Clin Lymphoma Myeloma Leuk 2014; 14: 203–10. doi: 10.1016/j.clml.2013.10.011
doi: 10.1016/j.clml.2013.10.011